



This information was released for public disclosure on January 15, 2014 at 8.25 am CET.

CellaVision revises outlook for the full year: Sales growth in 2013

CellaVision announces that sales for the fourth quarter of 2013 has increased significantly in comparison with the corresponding quarter in 2012. This means that the company shows sales growth for the full year 2013, in contrast to what was communicated in the company's half-year report 2013.

The preliminary figures for the year 2013 show that CellaVision's revenue will increase by 5-7 per cent in comparison with 2012. Sales in the fourth quarter of 2013 will increase by 28-30 per cent in comparison to last year. The strong sales growth combined with cost control generate improved profitability.

In the second half of 2013 CellaVision saw a rise in the US and European markets but have not yet seen a confident trend improvement. The sales increase is partly explained by customers placing first quarter orders earlier than expected. CellaVision's inflow of orders is unevenly distributed over the year, depending on the distributors' sales and inventory levels. Traditionally, sales in the fourth quarter is strong.

As previously announced, CellaVision will publish its Year-end bulletin 2013 on February 13, 2014 with complete figures on financial development.

For more information, please contact:

Yvonne Mårtensson, CEO, CellaVision AB

Tel: +46708337782 | Email: yvonne.martensson@cellavision.com

About CellaVision

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2012 sales were SEK 170 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.